Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma
Aberrant methylation of promoter CpG islands is one of the most important inactivation mechanisms for tumor suppressor and tumor-related genes. Previous studies using genome-wide DNA methylation microarray analysis have suggested the existence of a CpG island methylator phenotype (CIMP) in lung adenocarcinomas. Although the biological behavior of these tumors varies according to tumor stage, no large-scale study has examined the CIMP in lung adenocarcinoma patients according to tumor stage. Furthermore, there have been no reported results regarding the clinical significance of each of the six CIMP markers. To examine the CIMP in patients with pulmonary adenocarcinoma after a surgical resection, we performed methylation analysis of six genes (CCNA1, ACAN, GFRA1, EDARADD, MGC45800, and p16 INK4A) in 230 pulmonary adenocarcinoma cases using the SEQUENOM MassARRAY platform. Fifty-four patients (28 %, 54/191) were in the CIMP-high (CIMP-H) group associated with high nodal stage (P = 0.007), the presence of micropapillary or solid histology (P = 0.003), and the absence of an epidermal growth factor receptor (EGFR) mutation (P = 0.002). By multivariate analysis, CIMP was an independent prognostic marker for overall survival (OS) and disease-specific survival (P = 0.03 and P = 0.43, respectively). In the stage I subgroups alone, CIMP-H patients had lower OS rates than the CIMP-low (CIMP-L) group (P = 0.041). Of the six CIMP markers, ACAN alone was significantly associated with patient survival. CIMP predicted the risk of progression independently of clinicopathological variables and enables the stratification of pulmonary adenocarcinoma patients, particularly among stage I cases.
KeywordsPulmonary adenocarcinoma Methylation CpG island methylator phenotype Prognosis
This study was supported by the Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (MEST) (2011–0030105). The specimens and data used in this study were provided by the Asan Bio-Resource Center of the Korea Biobank Network (Seoul, South Korea).
Compliance with Ethical Standards
Conflicts of interests
- 18.Choi S, Kim HR, Sung CO, Kim J, Kim S, Ahn SM, Choi CM, Chun SM, Choi EK, Kim SW, Kim YH, Lee JY, Song JS, Kim D, Haq F, Lee SY, Lee JE, Jung WR, Jang HY, Yang E, Lee C, Yu E, Kong G, Baek D, Jang SJ: Genomic alterations in the rb pathway indicate prognostic outcomes of early-stage lung adenocarcinoma. Clin Cancer Res. 2015;21:2613–23.Google Scholar
- 19.Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011;8:381–5.CrossRefPubMedGoogle Scholar
- 30.Strauss GM, Herndon 2nd JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage Ib non-small-cell lung cancer: Calgb 9633 with the cancer and leukemia group b, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol. 2008;26:5043–51.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Sumiyoshi S, Yoshizawa A, Sonobe M, Kobayashi M, Fujimoto M, Tsuruyama T, et al. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages. Lung Cancer. 2013;81:53–9.CrossRefPubMedGoogle Scholar
- 37.Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (n2) patients. J Thorac Oncol. 2013;8:461–8.CrossRefPubMedGoogle Scholar